Lupin an­nounces new chief ex­ec­u­tive of US mar­ket

BioSpectrum (Asia) - - People News -

In­dian pharma ma­jor Lupin Lim­ited has an­nounced the ap­point­ment of Alok Sonig as CEO – US Gener­ics and Global Head – Gener­ics R&D & Biosimilars. Alok will lead and have over­all re­spon­si­bil­ity for the US Gener­ics busi­ness in­clud­ing Re­search & De­vel­op­ment in In­dia and the US and the Com­mer­cial side of the busi­ness in the US. He will also be re­spon­si­ble for Lupin’s global Biosimilars busi­ness.

With over 23 years of ex­pe­ri­ence in the in­dus­try, Alok brings an es­tab­lished track record of suc­cess in the Phar­ma­ceu­ti­cal and Health­care sec­tors to Lupin. Most re­cently, Alok was CEO of De­vel­oped Mar­kets (US, Canada, Europe and Ja­pan) at Dr. Reddy’s. He joined Dr. Reddy’s in 2012 and ran their In­dia busi­ness till 2015 be­fore mov­ing back to the US to run their North Amer­ica busi­ness. Prior to Dr. Reddy’s, Alok spent nearly 15 years at Bris­tol-My­ers Squibb, where he held sev­eral po­si­tions of in­creas­ing re­spon­si­bil­i­ties in Gen­eral Man­age­ment, Coun­try lead­er­ship roles, Global Strat­egy and Mar­ket­ing. Alok holds a Bach­e­lor’s of En­gi­neer­ing from Pun­jab En­gi­neer­ing Col­lege in In­dia, and an MBA from Amer­i­can Univer­sity,

Washington, D.C.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.